Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited covers the three-month period ended June 30, 2020 (Fiscal Year 2020 Q1). The report includes consolidated financial results prepared under International Financial Reporting Standards (IFRS). The filing was submitted on July 31, 2020.
Key Financial Metrics
| Metric | Q1 FY2020 (JPY) | Q1 FY2019 (JPY) | Change (%) |
|---|---|---|---|
| Revenue | 801,850 Million | 849,121 Million | (5.6%) |
| Operating Profit | 167,285 Million | 45,167 Million | 270.4% |
| Profit Before Tax | 130,291 Million | 10,115 Million | N/A |
| Net Profit (Attributable to Owners) | 82,511 Million | 7,009 Million | N/A |
| Basic EPS | 52.93 JPY | 4.51 JPY | N/A |
| Core Operating Profit | 280.9 Billion | 283.0 Billion | (0.7%) |
| Underlying Core EPS | 122 JPY | 128 JPY | (4.7%) |
Balance Sheet (as of June 30, 2020):
- Total Assets: 12,613,852 Million JPY
- Total Equity: 4,690,764 Million JPY
- Cash and Cash Equivalents: 589,787 Million JPY
- Bonds and Loans: 5,075,000 Million JPY (Carrying amount)
Cash Flow (Q1 FY2020):
- Operating Cash Flow: 145,861 Million JPY (Inflow)
- Investing Cash Flow: 662 Million JPY (Inflow)
- Financing Cash Flow: (192,765) Million JPY (Outflow)
Material Changes vs. Prior Period
Reported Operating Profit surged 270.4% year-over-year, primarily driven by a one-time gain of approximately 60.2 billion JPY related to the release of the obligation to divest the pipeline compound SHP647 following a European Commission decision. This was partially offset by a loss of 18.6 billion JPY from the remeasurement of contingent consideration assets related to the XIIDRA divestiture.
Revenue declined 5.6% to 801.9 billion JPY. The decline was attributed to a 4.0 percentage point negative impact from the appreciation of the yen, divestitures completed in the prior fiscal year, and generic erosion. However, core therapeutic areas showed resilience:
- Gastroenterology (GI): Revenue increased 8.9%, driven by strong sales of ENTYVIO (+20.7%) and TAKECAB (+10.6%).
- PDT Immunology: Revenue increased 14.8%, fueled by strong demand for immunoglobulin products like GAMMAGARD LIQUID.
- Rare Diseases: Revenue decreased 8.2%, impacted by the U.S. recall of NATPARA and competitive pressure on ADVATE.
- Neuroscience: Revenue decreased 4.5%, affected by the yen appreciation and reduced patient visits due to COVID-19 (e.g., VYVANSE).
Cost of Sales decreased 18.4% largely due to a reduction in non-cash charges related to the Shire Acquisition inventory step-up. SG&A and R&D expenses also decreased due to cost synergies and reduced travel/event spending related to COVID-19.
Guidance, Outlook, and Risks
Revised Full Year Forecast (Fiscal Year Ending March 31, 2021):
- Revenue: 3,250.0 Billion JPY (Unchanged)
- Operating Profit: 395.0 Billion JPY (Increased by 40.0 Billion JPY from previous forecast)
- Profit Before Tax: 230.0 Billion JPY (Increased by 30.0 Billion JPY)
- Net Profit: 92.0 Billion JPY (Increased by 32.0 Billion JPY)
- Core Operating Profit: 984.0 Billion JPY (Unchanged)
- Core EPS: 420 JPY (Unchanged)
Management Guidance (Underlying Growth):
- Underlying Revenue Growth: Low-single-digit growth
- Underlying Core Operating Profit Growth: High-single-digit growth
- Underlying Core Operating Profit Margin: Low-30s %
- Underlying Core EPS Growth: Low-teen growth
Risks and Contingencies:
- COVID-19 Impact: While the overall financial impact in Q1 was not material, the company notes risks of supply chain disruptions, delays in clinical trials, and reduced patient visits for non-life-threatening conditions. The company is developing CoVIg-19, a potential therapy for COVID-19.
- Foreign Exchange: Fluctuations in currency rates remain a significant risk factor.
- Divestitures: The company continues to pursue divestitures of non-core assets to reduce debt.
Subsequent Event: On July 9, 2020, Takeda issued $7.0 billion in USD senior notes and €3.6 billion in Euro senior notes. Proceeds were used to prepay syndicated term loans and redeem existing senior notes.
Investor Verification Checklist
- One-Time Items: Verify the sustainability of the 60.2 billion JPY gain from the SHP647 liability release, as this significantly inflated reported Operating Profit and Net Profit.
- Core vs. Reported: Compare reported metrics against "Underlying" and "Core" metrics to assess organic business performance, which showed modest growth (Underlying Revenue +0.9%) despite reported revenue decline.
- Debt Reduction: Confirm the impact of the July 2020 bond issuance on the company's leverage ratio and interest expense profile.
- Product Pipeline: Monitor the status of the NATPARA recall resolution and the competitive landscape for ADVATE and VELCADE.
- COVID-19 Exposure: Assess the long-term impact of the pandemic on clinical trial timelines and patient adherence for chronic therapies in the Neuroscience and GI portfolios.